These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8565412)

  • 1. Serious interpretive error among three commercial systems for susceptibility testing of aztreonam. Aztreonam Study Group.
    Marshall SA
    Diagn Microbiol Infect Dis; 1995 Jul; 22(3):249-51. PubMed ID: 8565412
    [No Abstract]   [Full Text] [Related]  

  • 2. Correlation of aztreonam susceptibility results obtained with the MicroScan system to reference tests.
    Zimmer BL; Brattebo J; Bryant M; Capo A; Chipman A; Miller R; Wehr C; Van Pelt L
    Diagn Microbiol Infect Dis; 1997 Oct; 29(2):111-20. PubMed ID: 9368088
    [No Abstract]   [Full Text] [Related]  

  • 3. Interpretive errors using an automated system for the susceptibility testing of imipenem and aztreonam.
    Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 1995 Jan; 21(1):57-60. PubMed ID: 7789099
    [No Abstract]   [Full Text] [Related]  

  • 4. [Antibacterial mechanisms of synthetic monobactams against gram-negative bacilli].
    Mitsui K
    Hiroshima Daigaku Shigaku Zasshi; 1987 Dec; 19(2):373-90. PubMed ID: 3504872
    [No Abstract]   [Full Text] [Related]  

  • 5. Synthesis and antimicrobial properties of substituted 3-aminoxypropionyl and 3-aminoxy-(E)-2-methoxyiminopropionyl monobactams.
    Balsamo A; Macchia B; Orlandini E; Rossello A; Macchia F; Broccali G; Fonio W
    Farmaco; 1990 Jul; 45(7-8):879-88. PubMed ID: 2282121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and development of the monobactams.
    Sykes RB; Bonner DP
    Rev Infect Dis; 1985; 7 Suppl 4():S579-93. PubMed ID: 3909315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and antibacterial evaluation of new monobactams.
    Thu ZM; Sun J; Ji J; He L; Ji J; Iqbal Z; Myo KK; Gao Y; Zhai L; Mu Y; Tang D; Vidari G; Yang H; Yang Z
    Bioorg Med Chem Lett; 2021 May; 39():127878. PubMed ID: 33636305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The in-vitro activity of SQ 82,291, a new monobactam, in comparison with aztreonam.
    García-Rodríguez JA; García-Sánchez JE; Plata A; Trujillano I
    J Antimicrob Chemother; 1986 Mar; 17(3):303-7. PubMed ID: 3754552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Belgian multicentre study on the in vitro activity of cefepime against gram-negative bacilli.
    Verbist L; Glupczynski Y
    Acta Clin Belg; 1996; 51(1):28-35. PubMed ID: 8669160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of the in vitro activity of aztreonam on 1990 gram-negative bacterial strains recently isolated in Campania hospitals].
    Covelli I; Bolletti-Censi M; Fortunato A; Guarino A; Spagnoletti G; Amato G; Nani E; Anzivino D; Lavitola A; Gulletta E
    Boll Ist Sieroter Milan; 1986; 65(1):22-31. PubMed ID: 3521671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of monobactams as antibacterial agents against gram-negative bacteria.
    Fu HG; Hu XX; Li CR; Li YH; Wang YX; Jiang JD; Bi CW; Tang S; You XF; Song DQ
    Eur J Med Chem; 2016 Mar; 110():151-63. PubMed ID: 26827160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of the intestinal flora of mice by treatment with aztreonam and tigemonam.
    van Ogtrop ML; Guiot HF; Mattie H; van Strijen E; Sekh BR; van Furth R
    Antimicrob Agents Chemother; 1991 May; 35(5):983-5. PubMed ID: 1854181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro antibacterial activity of aztreonam against gram-negative bacilli isolated in 1985.
    Miyake Y; Yokoyama T; Nakano H; Kuwabara M; Yamakido M; Suginaka H
    Hiroshima J Med Sci; 1988 Sep; 37(3):115-7. PubMed ID: 3248945
    [No Abstract]   [Full Text] [Related]  

  • 14. Susceptibility of 310 nonfermentative gram-negative bacteria to aztreonam, carumonam, ciprofloxacin, ofloxacin and fleroxacin.
    Appelbaum PC; Spangler SK; Tamarree T
    Chemotherapy; 1988; 34(1):40-5. PubMed ID: 3127127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survey of antibiotic susceptibility among gram-negative bacilli at a cancer center.
    Rolston KV; Elting L; Waguespack S; Ho DH; LeBlanc B; Bodey GP
    Chemotherapy; 1996; 42(5):348-53. PubMed ID: 8874974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aztreonam: antibacterial activity, beta-lactamase stability, and interpretive standards and quality control guidelines for disk-diffusion susceptibility tests.
    Barry AL; Thornsberry C; Jones RN; Gavan TL
    Rev Infect Dis; 1985; 7 Suppl 4():S594-604. PubMed ID: 3909316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conjugation of Aztreonam, a Synthetic Monocyclic β-Lactam Antibiotic, to a Siderophore Mimetic Significantly Expands Activity Against Gram-Negative Bacteria.
    Liu R; Miller PA; Miller MJ
    ACS Infect Dis; 2021 Nov; 7(11):2979-2986. PubMed ID: 34668698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility of 89,517 gram-negative isolates to aztreonam and other antibiotics.
    Lindsay G; Woods P
    Chemioterapia; 1987 Jun; 6(2 Suppl):106. PubMed ID: 3509363
    [No Abstract]   [Full Text] [Related]  

  • 19. [Comparative in vitro activity of 2 monobactams (RO 172301 (AMA 1080)and aztreonam), ceftazidime and cefotaxime on Gram-negative bacilli].
    Thabaut A; Meyran M; Huerre M
    Pathol Biol (Paris); 1985 May; 33(5):404-7. PubMed ID: 3929217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of the pharmacokinetics and pharmacodynamics of aztreonam.
    Ramsey C; MacGowan AP
    J Antimicrob Chemother; 2016 Oct; 71(10):2704-12. PubMed ID: 27334663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.